[go: up one dir, main page]

PL378333A1 - Sposoby profilaktyki i leczenia choroby Alzheimera (AD) - Google Patents

Sposoby profilaktyki i leczenia choroby Alzheimera (AD)

Info

Publication number
PL378333A1
PL378333A1 PL378333A PL37833304A PL378333A1 PL 378333 A1 PL378333 A1 PL 378333A1 PL 378333 A PL378333 A PL 378333A PL 37833304 A PL37833304 A PL 37833304A PL 378333 A1 PL378333 A1 PL 378333A1
Authority
PL
Poland
Prior art keywords
arg
glu
asp
tyr
phe
Prior art date
Application number
PL378333A
Other languages
English (en)
Other versions
PL209989B1 (pl
Inventor
Frank Mattner
Original Assignee
Affiris Forschungs-Und Entwicklungs Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Forschungs-Und Entwicklungs Gmbh filed Critical Affiris Forschungs-Und Entwicklungs Gmbh
Publication of PL378333A1 publication Critical patent/PL378333A1/pl
Publication of PL209989B1 publication Critical patent/PL209989B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
PL378333A 2003-01-14 2004-01-13 Zastosowanie związku peptydowego oraz szczepionka przeciwko chorobie Alzheimera PL209989B1 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT362003 2003-01-14
AT0146403A AT413945B (de) 2003-01-14 2003-09-17 Impfstoff für die alzheimer-krankheit
PCT/EP2004/000162 WO2004062556A2 (en) 2003-01-14 2004-01-13 Methods for preventing and treating alzheimer’s disease (ad)

Publications (2)

Publication Number Publication Date
PL378333A1 true PL378333A1 (pl) 2006-03-20
PL209989B1 PL209989B1 (pl) 2011-11-30

Family

ID=32714004

Family Applications (1)

Application Number Title Priority Date Filing Date
PL378333A PL209989B1 (pl) 2003-01-14 2004-01-13 Zastosowanie związku peptydowego oraz szczepionka przeciwko chorobie Alzheimera

Country Status (15)

Country Link
US (2) US7732568B2 (pl)
EP (2) EP1583774B1 (pl)
JP (2) JP4547373B2 (pl)
CN (2) CN102526699A (pl)
AT (3) AT413945B (pl)
CA (1) CA2513218C (pl)
CY (2) CY1107146T1 (pl)
DE (2) DE602004009705T2 (pl)
DK (2) DK1679319T3 (pl)
ES (2) ES2296084T3 (pl)
HK (1) HK1091499A1 (pl)
PL (1) PL209989B1 (pl)
PT (2) PT1679319E (pl)
SI (1) SI1583774T1 (pl)
WO (1) WO2004062556A2 (pl)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004056318A2 (en) 2002-12-19 2004-07-08 New York University Method for treating amyloid disease
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
AT413336B (de) * 2003-09-12 2006-02-15 Mattner Frank Dr Apherese-vorrichtung
US20070172496A1 (en) * 2004-01-28 2007-07-26 Curix Aps Conjugates of amyloid proteins as vaccines for amyloid-related diseases
AT500483B1 (de) 2004-07-13 2006-01-15 Mattner Frank Dr Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung
AT413946B (de) * 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
PL1976877T5 (pl) 2005-11-30 2017-09-29 Abbvie Inc Przeciwciała monoklonalne przeciwko białku amyloidu beta oraz ich zastosowania
US8691224B2 (en) 2005-11-30 2014-04-08 Abbvie Inc. Anti-Aβ globulomer 5F7 antibodies
WO2007068412A2 (en) 2005-12-12 2007-06-21 Ac Immune Sa A beta 1-42 specific monoclonal antibodies with therapeutic properties
EP1878747A1 (en) 2006-07-11 2008-01-16 greenovation Biotech GmbH Glyco-engineered antibodies
US7892544B2 (en) 2006-07-14 2011-02-22 Ac Immune Sa Humanized anti-beta-amyloid antibody
US8455626B2 (en) * 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
AU2008267038B2 (en) * 2007-06-12 2014-08-07 Ac Immune S.A. Humanized antibodies to amyloid beta
US8048420B2 (en) * 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
CN101998863B (zh) * 2007-10-05 2015-09-16 基因技术公司 抗淀粉状蛋白β抗体在眼病中的用途
WO2009048539A2 (en) * 2007-10-05 2009-04-16 Genentech, Inc. Monoclonal antibody
NZ601858A (en) * 2007-10-05 2014-03-28 Genentech Inc Methods and compositions for diagnosis and treatment of amyloidosis
WO2009054537A1 (ja) 2007-10-25 2009-04-30 Kagoshima University アミロイドβペプチドのミミック分子を用いたペプチドワクチン
JP5185946B2 (ja) * 2007-10-29 2013-04-17 Ｔａｏヘルスライフファーマ株式会社 抗体及びその利用
EP2278998A1 (en) 2008-04-17 2011-02-02 Declion Pharmaceuticals, Inc. Design and synthesis of directed sequence polymer compositions and antibodies thereof for the treatment of protein conformational disorders
US20110092436A1 (en) * 2008-06-12 2011-04-21 Affiris Ag Compounds for treating symptoms associated with parkinson's disease
AT506819B1 (de) * 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
AT509611B1 (de) * 2008-06-12 2012-04-15 Affiris Forschungs-Und Entwicklungs Gmbh Vakzin
MX336196B (es) 2010-04-15 2016-01-11 Abbvie Inc Proteinas de union a amiloide beta.
US9221900B2 (en) 2010-07-30 2015-12-29 Ac Immune S.A. Methods for identifying safe and functional humanized antibodies
CN105348387B (zh) 2010-08-14 2020-08-25 Abbvie 公司 β淀粉样蛋白结合蛋白
US20120328605A1 (en) * 2010-10-27 2012-12-27 Daniel Larocque Compositions and uses
GB201113570D0 (en) * 2011-08-05 2011-09-21 Glaxosmithkline Biolog Sa Vaccine
ES2496341T3 (es) 2011-10-04 2014-09-18 Affiris Ag Procedimiento para detectar anticuerpos Aß-específicos en una muestra biológica
EP2787347A1 (en) 2013-04-03 2014-10-08 Affiris AG Method for detecting Aß-specific antibodies in a biological sample
US10381614B2 (en) * 2013-04-17 2019-08-13 Samsung Sdi Co., Ltd. Battery module
WO2015165961A1 (en) 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CN108472344A (zh) 2015-11-03 2018-08-31 阿费里斯股份公司 用于针对人患者中的自身抗原的疫苗接种方法
CN105237628B (zh) * 2015-11-17 2018-08-07 南开大学 一种用于治疗阿尔兹海默症的多肽
CN107022019B (zh) * 2016-11-24 2020-10-30 桂林医学院 一种用于脑内降铁除自由基的多肽、制备方法与应用
JP7368856B2 (ja) 2017-07-25 2023-10-25 トゥルーバインディング，インコーポレイテッド Ｔｉｍ－３とそのリガンドとの相互作用の遮断によるがん治療
AU2023223603A1 (en) 2022-02-28 2024-08-22 Tridem Bioscience Gmbh & Co Kg A CONJUGATE CONSISTING OF OR COMPRISING AT LEAST A ß-GLUCAN OR A MANNAN.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) * 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US5650489A (en) * 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
GB9022190D0 (en) 1990-10-12 1990-11-28 Perham Richard N Immunogenic material
US5639603A (en) * 1991-09-18 1997-06-17 Affymax Technologies N.V. Synthesizing and screening molecular diversity
US7964192B1 (en) * 1997-12-02 2011-06-21 Janssen Alzheimer Immunotherapy Prevention and treatment of amyloidgenic disease
US6088993A (en) 1999-02-05 2000-07-18 Irace; Francisco D. Closure system
JP2002537354A (ja) * 1999-02-25 2002-11-05 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム ペプチド、及びＨ．ｉｎｆｌｕｅｎｚａｅのプロテインＤ由来の担体を含む免疫原
US6703491B1 (en) * 1999-03-17 2004-03-09 Exelixis, Inc. Drosophila sequences
AU784568B2 (en) * 1999-09-03 2006-05-04 Ramot At Tel-Aviv University Ltd Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
KR20020079983A (ko) * 2000-03-03 2002-10-21 스미스클라인 비이참 바이오로지칼즈 에스.에이. 죽상경화증의 치료를 위한 백신
GB0024200D0 (en) * 2000-10-03 2000-11-15 Smithkline Beecham Sa Component vaccine
EP1287831B1 (de) 2001-09-03 2006-11-22 Bio Life Science Forschungs- und Entwicklungsges.m.b.H. Antigen-Mimotope und Vakzine gegen Krebserkrankungen
PT1788394E (pt) 2002-05-07 2009-08-13 Pasteur Institut Rastreio de péptidos que inibem a ligação da pp1c às proteínas bcl-2, bcl-xi e bcl-w

Also Published As

Publication number Publication date
PT1583774E (pt) 2010-04-07
DE602004025668D1 (de) 2010-04-08
JP4547373B2 (ja) 2010-09-22
CN102526699A (zh) 2012-07-04
EP1583774B1 (en) 2010-02-24
WO2004062556A8 (en) 2004-10-21
CN1826354B (zh) 2014-01-08
EP1583774A2 (en) 2005-10-12
DE602004009705D1 (de) 2007-12-06
JP5282058B2 (ja) 2013-09-04
ES2296084T3 (es) 2008-04-16
DK1583774T3 (da) 2010-05-03
HK1091499A1 (en) 2007-01-19
CA2513218C (en) 2013-06-25
ES2339447T3 (es) 2010-05-20
US20060111301A1 (en) 2006-05-25
ATA14642003A (de) 2005-11-15
SI1583774T1 (sl) 2010-06-30
JP2006515876A (ja) 2006-06-08
AT413945B (de) 2006-07-15
EP1679319B1 (en) 2007-10-24
CN1826354A (zh) 2006-08-30
EP1679319A1 (en) 2006-07-12
PL209989B1 (pl) 2011-11-30
WO2004062556A3 (en) 2004-09-16
US7732568B2 (en) 2010-06-08
CA2513218A1 (en) 2004-07-29
ATE458753T1 (de) 2010-03-15
DK1679319T3 (da) 2008-01-28
PT1679319E (pt) 2008-01-10
AU2004204349A1 (en) 2004-07-29
JP2010174024A (ja) 2010-08-12
CY1110634T1 (el) 2015-04-29
ES2339447T8 (es) 2011-05-26
CY1107146T1 (el) 2012-05-23
DE602004009705T2 (de) 2008-06-05
WO2004062556A2 (en) 2004-07-29
ATE376559T1 (de) 2007-11-15
US20110015131A1 (en) 2011-01-20

Similar Documents

Publication Publication Date Title
SI1583774T1 (sl) Postopki za preprečevanje in zdravljenje Alzheimerjeve bolezni AD
TW200602071A (en) Methods for preventing and treating alzheimer's disease (ad)
ATE283289T1 (de) Monoklonale antikörper, antigene sowie diagnose und therapie von bösartigen krankheiten
WO2001068708A3 (en) Human and humanized fap-alpha-specific antibodies
AU2002302255A1 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
AT500379B1 (de) Tau-proteine
WO2001039796A3 (en) Vaccine for the prevention and treatment of alzheimer's and amyloid related diseases
BR0213565A (pt) Anticorpo de anti-tnf alfa modificado
WO2004006952A3 (en) Therapeutic tuberculosis vaccines
WO2000073430A3 (de) Vakzine gegen konformationsabhängige antigene sowie gegen antigene, die keine oder nicht ausschliesslich proteine oder peptide sind
DE60313437D1 (de) Mhc klasse i peptidepitope des humanen tumorassoziierten antigens 5t4
WO2003068815A3 (en) Mhc class ii peptide epitope of 5t4 antigen
WO2004113386A3 (en) Modified hirudin proteins and t-cell epitopes in hirudin
EE200000478A (et) Peptiid, seda kodeeriv geen, diagnostiline reagent ja diagnostiline reaktiivikomplekt ning vaktsiinkasutamiseks riketsioosi ravis
HUP0303150A2 (hu) Csökkentett immunogenitású, módosított keratinocita növekedési faktor (KGF)
WO2002070563A3 (en) Nuclear hormone receptor ligand binding domain
WO2007030771A3 (en) Targeted identification of immunogenic peptides
HUP0402160A2 (hu) T-sejt-epitópok a karboxipeptidáz-G2-ben
WO2004050703A8 (en) Splice variant of the human pituitary growth hormone
WO2002070560A3 (en) Nuclear hormone receptor ligand binding domain
WO2004011496A3 (en) Novel t-cell proteins, peptides and antibodies derived therefrom and uses thereof
AU2002350406A1 (en) Identification of ses-3 (spr-5) in c. elegans and the uses of the same
DE60122721D1 (de) Diagnostische verwendungen des t-zell proteins tzon7, der davon abgeleiteten peptide und des antikörpers
WO2002008393A3 (en) Serine protease from yersinia enterocolitica
WO2002046380A3 (en) Protein kinase